Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Teig

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The Pediatric Infectious Disease Journal|January 13, 2023
Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case SeriesCornelius Rau, Lorenz Auer-Hackenberg, Hedwig E Deubzer, et al.
Iscience|February 3, 2025
Pathogenic <i>KIAA0586/TALPID3</i> variants are associated with defects in primary and motile ciliaJacqueline E Taudien, Diana Bracht, Heike Olbrich, et al.
Nature|November 17, 2017
Regeneration of the entire human epidermis using transgenic stem cellsTobias Hirsch, Tobias Rothoeft, Norbert Teig, et al.
Neonatology|January 4, 2018
Influence of PCO2 Control on Clinical and Neurodevelopmental Outcomes of Extremely Low Birth Weight InfantsUlrich H Thome, Jens Dreyhaupt, Orsolya Genzel-Boroviczeny, et al.
The Lancet. Respiratory Medicine|June 20, 2015
Permissive hypercapnia in extremely low birthweight infants (PHELBI): a randomised controlled multicentre trialUlrich H Thome, Orsolya Genzel-Boroviczeny, Bettina Bohnhorst, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|January 15, 2017
Neurodevelopmental outcomes of extremely low birthweight infants randomised to different PCO<sub>2</sub> targets: the PHELBI follow-up studyUlrich H Thome, Orsolya Genzel-Boroviczeny, Bettina Bohnhorst, et al.
The Lancet. Respiratory Medicine|April 21, 2024
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trialSascha Meyer, Johannes Bay, Axel R Franz, et al.
JAMA Pediatrics|August 5, 2024
Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants: The PRIMAL Randomized Clinical TrialThea Van Rossum, Annette Haiß, Rebecca L Knoll, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|June 29, 2019
Active perinatal care of preterm infants in the German Neonatal NetworkAlexander Humberg, Christoph Härtel, Tanja K Rausch, et al.
Eclinicalmedicine|November 10, 2025
Corrigendum to "Two-year outcomes after early postnatal high-dose fat-soluble enteral vitamin A supplementation in extremely low birth weight infants: follow-up of the NeoVitaA randomized controlled trial"Martin Poryo, Ludwig Gortner, Johannes Bay, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Pediatric Infectious Disease Journal|January 13, 2023
Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case SeriesCornelius Rau, Lorenz Auer-Hackenberg, Hedwig E Deubzer, et al.
Iscience|February 3, 2025
Pathogenic <i>KIAA0586/TALPID3</i> variants are associated with defects in primary and motile ciliaJacqueline E Taudien, Diana Bracht, Heike Olbrich, et al.
Nature|November 17, 2017
Regeneration of the entire human epidermis using transgenic stem cellsTobias Hirsch, Tobias Rothoeft, Norbert Teig, et al.
Neonatology|January 4, 2018
Influence of PCO2 Control on Clinical and Neurodevelopmental Outcomes of Extremely Low Birth Weight InfantsUlrich H Thome, Jens Dreyhaupt, Orsolya Genzel-Boroviczeny, et al.
The Lancet. Respiratory Medicine|June 20, 2015
Permissive hypercapnia in extremely low birthweight infants (PHELBI): a randomised controlled multicentre trialUlrich H Thome, Orsolya Genzel-Boroviczeny, Bettina Bohnhorst, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|January 15, 2017
Neurodevelopmental outcomes of extremely low birthweight infants randomised to different PCO<sub>2</sub> targets: the PHELBI follow-up studyUlrich H Thome, Orsolya Genzel-Boroviczeny, Bettina Bohnhorst, et al.
The Lancet. Respiratory Medicine|April 21, 2024
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trialSascha Meyer, Johannes Bay, Axel R Franz, et al.
JAMA Pediatrics|August 5, 2024
Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants: The PRIMAL Randomized Clinical TrialThea Van Rossum, Annette Haiß, Rebecca L Knoll, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|June 29, 2019
Active perinatal care of preterm infants in the German Neonatal NetworkAlexander Humberg, Christoph Härtel, Tanja K Rausch, et al.
Eclinicalmedicine|November 10, 2025
Corrigendum to "Two-year outcomes after early postnatal high-dose fat-soluble enteral vitamin A supplementation in extremely low birth weight infants: follow-up of the NeoVitaA randomized controlled trial"Martin Poryo, Ludwig Gortner, Johannes Bay, et al.
Pageof 4